Lab
CDT GMSP, INC
CDT GMSP, INC was paid $4.66M by Medicaid between Jan 2018 and Dec 2024, across 74 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 15% of everything it billed.
33Billing provider infoCDT GMSP, INC
BAYAMON, PR 00961
BAYAMON, PR 00961
33aNPI1790750529assigned 02/23/2006
33bProvider typeClinical Medical Laboratory
28Total paid$4.66M
24GClaims320,668
24DCodes billed74
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Puerto Rico
Rank by total paid#15 of 777
Median peer was paid$278K
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,859 | $29K | |
| 2019 | 39,993 | $500K | |
| 2020 | 42,596 | $658K | |
| 2021 | 44,610 | $755K | |
| 2022 | 41,630 | $751K | |
| 2023 | 74,986 | $1.30M | |
| 2024incomplete | 37,994 | $663K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 15% | 16,732 | 13,676 | $697K |
| 84443 | Thyroid stimulating hormone (TSH) | 9.7% | 24,282 | 21,867 | $450K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 9.3% | 30,556 | 12,627 | $434K |
| 80061 | Lipid panel | 8.9% | 29,269 | 26,425 | $415K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.3% | 34,590 | 30,962 | $293K |
| 80053 | Comprehensive metabolic panel | 6.2% | 25,763 | 23,156 | $289K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.3% | 6,078 | 5,418 | $246K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.2% | 6,043 | 5,381 | $244K |
| 82274 | 3.8% | 9,915 | 8,818 | $175K | |
| 86701 | 3.1% | 14,368 | 12,899 | $144K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.0% | 4,110 | 3,617 | $141K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.7% | 11,798 | 10,699 | $127K |
62 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.6% | 2,492 | $121K |
| 86803 | 2.6% | 7,489 | $121K | |
| 81000 | 2.4% | 32,393 | $111K | |
| 84153 | 1.6% | 3,700 | $75K | |
| 82043 | 1.3% | 9,186 | $59K | |
| 86738 | 1.3% | 3,482 | $59K | |
| 86328 | 1.1% | 2,692 | $50K | |
| 86592 | <1% | 7,916 | $37K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,707 | $24K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,025 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,563 | $22K |
| 82607 | <1% | 1,098 | $21K | |
| 87276 | <1% | 2,316 | $21K | |
| 87275 | <1% | 2,314 | $18K | |
| 82670 | <1% | 475 | $18K | |
| 80074 | <1% | 339 | $16K | |
| 84436 | <1% | 2,099 | $16K | |
| 83655 | <1% | 1,107 | $15K | |
| 83001 | <1% | 610 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,142 | $15K |
| 87177 | <1% | 2,426 | $13K | |
| 80050 | General health panel | <1% | 1,327 | $12K |
| 83002 | <1% | 469 | $12K | |
| 83525 | <1% | 931 | $12K | |
| 84439 | <1% | 1,159 | $11K | |
| 86304 | <1% | 395 | $11K | |
| 84479 | <1% | 1,337 | $9K | |
| 86038 | <1% | 588 | $8K | |
| 85730 | <1% | 1,244 | $7K | |
| 82728 | <1% | 406 | $7K | |
| 82947 | <1% | 1,714 | $6K | |
| 85651 | <1% | 1,720 | $6K | |
| 85610 | <1% | 1,310 | $5K | |
| 86140 | <1% | 806 | $4K | |
| 82951 | <1% | 379 | $4K | |
| 82570 | <1% | 590 | $3K | |
| 87070 | <1% | 315 | $3K | |
| 86703 | <1% | 116 | $2K | |
| 84154 | <1% | 60 | $1K | |
| 83540 | <1% | 141 | $1K | |
| 82746 | <1% | 55 | $1K | |
| 86376 | <1% | 66 | $1K | |
| 84550 | <1% | 203 | $980.58 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 52 | $498.75 |
| 84460 | <1% | 168 | $460.50 | |
| 84450 | <1% | 186 | $456.71 | |
| 84403 | <1% | 13 | $446.18 | |
| 86696 | <1% | 15 | $354.22 | |
| 83550 | <1% | 30 | $332.08 | |
| 84432 | <1% | 14 | $318.64 | |
| 82378 | <1% | 12 | $289.50 | |
| 84703 | <1% | 25 | $255.89 | |
| 82270 | <1% | 56 | $208.98 | |
| 86695 | <1% | 13 | $201.88 | |
| 87899 | <1% | 45 | $190.00 | |
| 86430 | <1% | 12 | $83.11 | |
| 87850 | <1% | 27 | $68.76 | |
| 86431 | <1% | 14 | $37.57 | |
| 84156 | <1% | 26 | $5.19 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 494 | $0.61 |
| 87270 | 0% | 47 | $0.00 | |
| 82465 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZAYAS, ILIA (EXUCUTIVE DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| CDT GMSP INC | Bayamon, PR | $159K |
| CDT G.M,s.P., INC | Bayamon, PR | $33K |
| Optica Cdtgmsp | Bayamon, PR | $6K |
| Grupo Medico San Pablo INC | Bayamon, PR | $2K |
| Cooperativa De Facultad Medica Sanacoop | Bayamon, PR | $606.13 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.